ARS Pharma Reports Q1 2026 Earnings
ARS Pharma (SPRY) reported first-quarter earnings with total revenue of $22.7 million, driven by strong performance from its product neffy and international agreements. The company highlighted significant growth in U.S. net product revenue for neffy, expansion into Medicaid coverage across multiple states, progress on removing prior authorization barriers at major insurers like CVS Caremark, and a new retail pharmacy cash price program to reduce patient costs.
Tickers: $SPRY
Topics: market_access pharmaceuticals regulatory_progress revenue_growth